InspireMD, Inc. filed a Form 8-K on November 20, 2026, disclosing that the underwriters' overallotment option from its November 2026 public offering was exercised in full, closing on November 20, 2026, and generating approximately $5.3 million in additional net proceeds.

Key Highlights

  • Option exercised in full: On November 18, 2026, Lake Street Capital Markets, LLC notified InspireMD it had elected to exercise the 30-day overallotment option in full.
  • Additional shares issued: The option covered up to 8,635,846 additional shares of common stock (par value $0.0001 per share).
  • Additional warrants issued: Option Common Warrants to purchase up to 6,490,384 shares of common stock were also issued upon exercise.
  • Additional proceeds: The overallotment closing raised approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses.
  • Original offering context: The initial offering, which closed November 16, 2026, raised approximately $34.9 million in net proceeds after underwriting discounts and before offering expenses.
  • Warrant agent: The Option Common Warrants are issued pursuant to a warrant agency agreement dated November 12, 2026, with Securities Transfer Corporation as warrant agent.

Overallotment Closing Details for InspireMD's November 2026 Offering

According to the filing, InspireMD, Inc. (NASDAQ:NSPR) previously closed a public offering on November 16, 2026, that included 7,342,308 shares of common stock, pre-funded warrants to purchase up to 50,350,000 shares of common stock, and accompanying Series L warrants to purchase up to 43,269,231 shares of common stock. That offering was conducted under the company's effective automatic shelf registration statement on Form S-3 (File No. 333-286309) and raised approximately $34.9 million in net proceeds after underwriting discounts and before offering expenses.

The filing discloses that, pursuant to the Underwriting Agreement dated November 13, 2026, by and among the company and Lake Street Capital Markets, LLC as representative of the several underwriters, the underwriters were granted a 30-day option to purchase up to an additional 8,635,846 shares of common stock and/or Common Warrants to purchase up to 6,490,384 shares of common stock, on the same terms and conditions as the original offering. The company reported that on November 18, 2026, the representative notified InspireMD of its election to exercise this option in full.

The overallotment closing occurred on November 20, 2026, the same date as the 8-K filing, and according to the company raised an additional approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses. The Option Common Warrants are to be issued under a warrant agency agreement dated November 12, 2026, between the company and Securities Transfer Corporation, acting as warrant agent. The filing was signed by Chief Executive Officer Marvin Slosman.

What Was Disclosed

InspireMD disclosed the full exercise of the underwriters' overallotment option from its November 2026 public offering, the closing of that overallotment on November 20, 2026, and the generation of approximately $5.3 million in additional net proceeds after underwriting discounts and before offering expenses.